Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.38 USD
-0.12 (-8.00%)
Updated May 29, 2024 04:00 PM ET
After-Market: $1.37 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 81 - 100 ( 394 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Amended Bempeg Collaboration Reflects the Limitations of a "Not Alpha" IL-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Upward Bias Exiting SITC; Target Increased to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Competitive Landscape Presents Tougher Challenges for Bempeg Post ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
2H19 Value Drivers Within Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D